Treatment of Prostate Cancer with a DBP-MAF-Vitamin D Complex to Target Angiogenesis and Tumorigenesis
Abstract
This study is investigating the potential combination therapy of DBP-maf and vitamin D on prostate tumors using human models of prostate cancer in a mouse model. Initial results have demonstrated that DBP-maf has both anti-angiogenic and anti-tumorigenic properties in vitro. Direct effects on tumor cell proliferation were observed in the parental but not metastatic form of LnCaP cells. This finding could be significant in characterizing differential responses of primary and metastatic tumor sites to therapies. These data will be integrated in the development of initial conditions for our in vivo tumor models. The use of a DBP-maf peptide was also tested in vitro assays. This work was undertaken based on a published report that the peptide represented the active portion of the molecule. Activity by the peptide would have made synthesis of DBP-maf considerably easier. It showed limited activity in the in vitro assays, however. Future in vivo studies will investigate the ability of DBP-maf to deliver vitamin D to tumor sites and inhibit angiogenesis and tumor growth.
Document Details
- Document Type
- Technical Report
- Publication Date
- Feb 01, 2006
- Accession Number
- ADA455984
Entities
People
- Michael W. Fannon
Organizations
- University of Kentucky